The Effect of Viloxazine Extended-Release Capsules on Functional Impairments Associated with Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents in Four Phase 3 Placebo-Controlled Trials

Neuropsychiatric Disease and Treatment ◽

10.2147/ndt.s312011 ◽

2021 ◽

Vol Volume 17 ◽

pp. 1751-1762

Author(s):

Azmi Nasser ◽

Joseph T Hull ◽

Tesfaye Liranso ◽

Gregory D Busse ◽

Zare Melyan ◽

...

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Children And Adolescents ◽

Attention Deficit ◽

Extended Release ◽

Controlled Trials ◽

Functional Impairments ◽

Phase 3 ◽

Hyperactivity Disorder

Download Full-text

Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior stimulant treatment

10.26226/morressier.5785edd1d462b80296c9a2a5 ◽

2016 ◽

Author(s):

Jiri Prochazka

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Children And Adolescents ◽

Attention Deficit ◽

Extended Release ◽

Stimulant Treatment ◽

Hyperactivity Disorder

Download Full-text

Evaluating the Likelihood to be Helped or Harmed after Treatment with Viloxazine Extended‐Release in Children and Adolescents with Attention Deficit/Hyperactivity Disorder

International Journal of Clinical Practice ◽

10.1111/ijcp.14330 ◽

2021 ◽

Author(s):

Azmi Nasser ◽

Alisa R. Kosheleff ◽

Joseph T. Hull ◽

Tesfaye Liranso ◽

Peibing Qin ◽

...

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Children And Adolescents ◽

Attention Deficit ◽

Extended Release ◽

Hyperactivity Disorder

Download Full-text

PIH23 Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents

Value in Health ◽

10.1016/j.jval.2011.08.927 ◽

2011 ◽

Vol 14 (7) ◽

pp. A401-A402 ◽

Cited By ~ 1

Author(s):

V. Sikirica ◽

M. Erder ◽

J. Xie ◽

D. Macaulay ◽

M. Diener ◽

...

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Cost Effectiveness ◽

Children And Adolescents ◽

Attention Deficit ◽

Adjunctive Therapy ◽

Extended Release ◽

Hyperactivity Disorder

Download Full-text

4.23 PIVOTAL PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF HLD200, A NOVEL DELAYED-RELEASE AND EXTENDED-RELEASE FORMULATION OF METHYLPHENIDATE, IN CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

Journal of the American Academy of Child & Adolescent Psychiatry ◽

10.1016/j.jaac.2016.09.218 ◽

2016 ◽

Vol 55 (10) ◽

pp. S170

Author(s):

Valerie K. Arnold ◽

Norberto J. DeSousa ◽

Bev Incledon ◽

Floyd R. Sallee ◽

Timothy E. Wilens ◽

...

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Attention Deficit ◽

Extended Release ◽

Efficacy And Safety ◽

Phase 3 ◽

Pivotal Phase ◽

Release Formulation ◽

Extended Release Formulation ◽

Hyperactivity Disorder ◽

Delayed Release

Download Full-text

Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology

CNS Drugs ◽

10.1007/s40263-013-0102-x ◽

2013 ◽

Vol 27 (11) ◽

pp. 943-953 ◽

Cited By ~ 21

Author(s):

Vanja Sikirica ◽

Robert L. Findling ◽

James Signorovitch ◽

M. Haim Erder ◽

Ryan Dammerman ◽

...

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Children And Adolescents ◽

Attention Deficit ◽

Extended Release ◽

Indirect Comparison ◽

Comparative Efficacy ◽

Hyperactivity Disorder ◽

Adjusted Indirect Comparison

Download Full-text

EPA-0666 – Long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, phase 3 randomized withdrawal study

European Psychiatry ◽

10.1016/s0924-9338(14)78034-4 ◽

2014 ◽

Vol 29 ◽

pp. 1 ◽

Cited By ~ 3

Author(s):

J. Newcorn ◽

V. Harpin ◽

M. Huss ◽

M. Johnson ◽

J.A. Ramos-Quiroga ◽

...

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Attention Deficit ◽

Extended Release ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Multicentre Phase ◽

Hyperactivity Disorder ◽

Term Maintenance

Download Full-text

Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents

Drugs of Today ◽

10.1358/dot.2010.46.5.1450095 ◽

2010 ◽

Vol 46 (5) ◽

pp. 299 ◽

Cited By ~ 13

Author(s):

D.F. Connor ◽

J. Rubin

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Children And Adolescents ◽

Attention Deficit ◽

Extended Release ◽

Hyperactivity Disorder

Download Full-text

Effect of methylphenidate formulation on attention deficit hyperactivity disorder (ADHD)-patients' adherence to medical treatment. A comparison of Medikinet retard® (extended-release [ER]) once daily and Medikinet® (immediate-release [IR]) twice daily in children and adolescents diagnosed with ADHD

http://isrctn.org/> ◽

10.1186/isrctn93724387 ◽

2012 ◽

Author(s):

Claudia Wachtarz

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Medical Treatment ◽

Children And Adolescents ◽

Attention Deficit ◽

Extended Release ◽

Immediate Release ◽

Once Daily ◽

Hyperactivity Disorder

Download Full-text

P.7.d.014 Guanfacine extended release: daytime sleepiness outcomes from a phase 3 clinical study in adolescents with attention-deficit/hyperactivity disorder

European Neuropsychopharmacology ◽

10.1016/s0924-977x(15)30920-2 ◽

2015 ◽

Vol 25 ◽

pp. S648-S649

Author(s):

A. Cutler ◽

L. Harper ◽

J. Young ◽

B. Adeyi ◽

B. Dirks ◽

...

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Clinical Study ◽

Attention Deficit ◽

Daytime Sleepiness ◽

Extended Release ◽

Phase 3 ◽

Hyperactivity Disorder

Download Full-text

Cost-effectiveness of guanfacine extended-release versus atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder in Canada

Value in Health ◽

10.1016/j.jval.2014.03.1250 ◽

2014 ◽

Vol 17 (3) ◽

pp. A213-A214

Author(s):

J. Lachaine ◽

V. Sikirica ◽

K. Mathurin

Keyword(s):

Attention Deficit Hyperactivity Disorder ◽

Cost Effectiveness ◽

Children And Adolescents ◽

Attention Deficit ◽

Extended Release ◽

Hyperactivity Disorder

Download Full-text